You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Details for New Drug Application (NDA): 216993


✉ Email this page to a colleague

« Back to Dashboard


NDA 216993 describes VANFLYTA, which is a drug marketed by Daiichi Sankyo Inc and is included in one NDA. It is available from one supplier. There are eleven patents protecting this drug. Additional details are available on the VANFLYTA profile page.

The generic ingredient in VANFLYTA is quizartinib dihydrochloride. One supplier is listed for this compound. Additional details are available on the quizartinib dihydrochloride profile page.
Summary for 216993
Tradename:VANFLYTA
Applicant:Daiichi Sankyo Inc
Ingredient:quizartinib dihydrochloride
Patents:11
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 216993
Generic Entry Date for 216993*:
Constraining patent/regulatory exclusivity:
FOR USE IN COMBINATION WITH STANDARD INDUCTION AND CONSOLIDATION, AND AS MAINTENANCE THERAPY FOLLOWING CONSOLIDATION CHEMOTHERAPY, FOR THE TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) THAT IS FLT3 INTERNAL TANDEM DUPLICATION (ITD)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 216993
Suppliers and Packaging for NDA: 216993
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VANFLYTA quizartinib dihydrochloride TABLET;ORAL 216993 NDA Daiichi Sankyo Inc. 65597-504 65597-504-04 1 BOTTLE in 1 CARTON (65597-504-04) / 14 TABLET, FILM COATED in 1 BOTTLE
VANFLYTA quizartinib dihydrochloride TABLET;ORAL 216993 NDA Daiichi Sankyo Inc. 65597-504 65597-504-28 1 BOTTLE in 1 CARTON (65597-504-28) / 28 TABLET, FILM COATED in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 17.7MG BASE
Approval Date:Jul 20, 2023TE:RLD:Yes
Regulatory Exclusivity Expiration:Jul 20, 2030
Regulatory Exclusivity Use:FOR USE IN COMBINATION WITH STANDARD INDUCTION AND CONSOLIDATION, AND AS MAINTENANCE THERAPY FOLLOWING CONSOLIDATION CHEMOTHERAPY, FOR THE TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) THAT IS FLT3 INTERNAL TANDEM DUPLICATION (ITD)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST
Regulatory Exclusivity Expiration:Jul 20, 2028
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:7,820,657Patent Expiration:Sep 26, 2028Product Flag?Substance Flag?YDelist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.